Immunity is a top health concern for consumers, and in response to that demand international ingredient supplier, Ganeden, recently developed a new immune-health solution called Staimune™. Now, the company is announcing additional studies confirming the immune benefits of the novel ingredient—which is gaining interest for formulation in a variety of food and beverage categories.
Staimune became available earlier this summer, and was developed using the inactivated cells of Ganeden’s patented and shelf-stable probiotic strain, GanedenBC30® (Bacillus coagulans GBI-30, 6086). Numerous previous studies of the strain showed its impressive immune-supporting benefits, which prompted the company’s science team to delve further into the bacteria’s relationship to immunity. Research demonstrated that even when inactivated, the cells of GanedenBC30 continued to confer immune health benefits, leading to the introduction of Staimune.
In the newest 2017 study, which was published in the Journal of Inflammation Research, previous lab studies were repeated to demonstrate that the immune effects of the cells were maintained, even when inactivated through a commercial production process (Jensen et al. Journal of Inflammation Research, 2017; 10: 107-117). The results show that the inactivated bacterial cells had similar immune activation and anti-inflammatory effects as live cells.
“This study, which is Ganeden’s 27th to be published, validates what the science team had previously discovered—that Staimune does an exceptional job supporting immune health regardless of the inactivation process,” said Dr. David Keller, vice president of scientific operations for Ganeden. “Science is a driving factor behind all Ganeden offerings, and the extensive and ongoing research being conducted on Staimune gives manufacturers confirmation that the new ingredient will deliver the immune benefits consumers want.”
Ganeden also recently completed a human trial, with initial findings demonstrating that Staimune supports a heathy immune system response to different stressors. Details of the trial will be released at a later date.
Staimune offers functional immune health benefits when fortified into any food or beverage category, with the biggest opportunities in shelf-stable beverages and high-water-activity products, where there are formulation challenges for live probiotics. The ingredient is FDA GRAS for usage in children and adults, and Ganeden has notified the FDA of self-affirmed GRAS for infant formula. It is also non-GMO, organic compliant and kosher, making it extremely accessible for use in a vast amount of applications, at cost-effective inclusion rates that don’t alter texture or flavor.
A copy of the full Staimune study can be found on the Dove Press website. For more information on the immune health ingredient and Ganeden’s other probiotic technologies, visit GanedenProbiotics.com.
Ganeden® is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30® its patented, FDA GRAS and highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden’s newest ingredient, Staimune™ is a patented probiotic technology comprising of inactivated GanedenBC30 cells, which have immune benefits. For more information about Ganeden and licensing opportunities, visit GanedenProbiotics.com.